ENDRA Life Sciences Inc. (NDRA) AI Stock Analysis

ENDRA Life Sciences Inc. pioneers technology to advance clinical diagnostic ultrasound capabilities, specializing in thermo-acoustic enhanced ultrasound. Its technology uses sound waves interacting with tissues, organs, and blood to address conditions like nonalcoholic fatty liver disease, with applications in thermoablative surgery monitoring, vascular imaging, and tissue perfusion. The company also offers diagnostic imaging technologies such as computed tomography (CT), magnetic resonance imaging (MRI), and traditional ultrasound to aid in diagnosing fractures, cancers, cardiac issues, and internal bleeding. Founded in 2007 and based in Ann Arbor, Michigan, it maintains a research collaboration with General Electric Company.

Annual revenue declined from $1.4M in FY2015 to $515,582 in FY2016, down 63.4%, and further dropped 31.8% to $351,622 in FY2017. In FY2018, revenue fell 98.2% to $6,174, resulting in a three-year revenue CAGR of -83.6% from FY2015 to FY2018. Over that period, net losses widened from -$2.3M in FY2015 to -$9.8M in FY2018, with research and development expenses reaching $4.7M in FY2018. For the trailing twelve months ending June 30, 2026, the company generated $0 in revenue, with a 0.0% operating margin and an EPS of -$6.26.

As of June 30, 2026, ENDRA Life Sciences held $1.7M in cash and short-term investments and $429,274 in total debt, resulting in net cash of $1.3M. Total assets stood at $7.9M against shareholders' equity of $6.3M. The company maintains a current ratio of 7.10 and a debt-to-equity ratio of 0.07. In FY2025, capital expenditures were $17,280. Its share count increased 18.1% over the past 5 years.

At a last close of $4.74 on October 16, 2026, ENDRA Life Sciences holds a market capitalization of $7.1M and an enterprise value of $8.5M. The stock trades at a price-to-book ratio of 1.5x. By comparison, the median of its US-listed Healthcare peers trades at a price-to-sales ratio of 4.1x, a trailing P/E of 24.6x, and a forward P/E of 17.3x. Over the past year, NDRA fell 32.3%, underperforming the S&P 500 return of 16.8%. Year to date, the stock has gained 4.6%.

Wall Street coverage consists of 1 Strong Buy rating, with 0 Buy, 0 Hold, 0 Sell, and 0 Strong Sell ratings. The mean price target is $25.00, representing an upside of 427.4% over the last close of $4.74. For the fiscal year ending December 31, 2026, the consensus EPS estimate is -$3.54 on expected revenue of $0. For the following fiscal year, 1 analyst projects revenue of $200,000 and an EPS of -$3.04. The company beat EPS estimates in 2 of the last 4 quarters, with next earnings scheduled for November 13, 2026.

This page is an AI-written research summary of ENDRA Life Sciences Inc. (NDRA). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: NDRA income statement, NDRA balance sheet, NDRA key metrics, NDRA analyst forecast, NDRA chart. See the NDRA stock overview for the latest quote and news.